Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Justin Mann

Interventional Pain Medicine Jacksonville, FL Medical Doctor

NPI 1790075703 CMS profile 1154795

15255 Max Leggett Pkwy Ste 5500, Fl 3, Jacksonville, FL 32218

Open in the dashboard

General payments

$243,124

619 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Mann of Jacksonville, FL is reported in the CMS Open Payments database as having received $243,124 across 619 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27,130 67
2024 General $43,011 98
2023 General $32,358 100
2022 General $68,297 143
2021 General $37,792 96
2020 General $31,420 75
2019 General $3,115 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Mann
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Justin Mann were reported at $27,130. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Justin Mann Interventional Pain Medicine median Middle half National median
2019 $3,115 $684 $216–$2,079 $163
2020 $31,420 $382 $122–$1,109 $114
2021 $37,792 $552 $167–$1,554 $132
2022 $68,297 $605 $187–$1,924 $149
2023 $32,358 $671 $195–$1,915 $160
2024 $43,011 $684 $206–$1,837 $164
2025 $27,130 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $203,896 355 payments
  2. Medtronic USA, Inc. $33,513 78 payments
  3. Kowa Pharmaceuticals America, Inc. $1,325 4 payments
  4. Abbott Laboratories $1,147 35 payments
  5. Amgen Inc. $380 16 payments
  6. Radius Health, Inc. $322 21 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $303 19 payments
  8. Boston Scientific Corporation $285 7 payments
  9. AbbVie, Inc. $243 13 payments
  10. Lundbeck LLC $231 11 payments
  11. Other $1,480 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $203,464 107 payments
  2. Travel and Lodging $23,128 132 payments
  3. Food and Beverage $14,185 377 payments
  4. Consulting Fee $2,255 2 payments
  5. Education $93 1 payment
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $124,522 224 payments
  2. KYPHON EXPRESS II KYPHOPAK TRAY $20,538 19 payments
  3. INTELLIS Spinal Cord Neurostimulation $18,972 17 payments
  4. VANTA ADAPTIVESTIM $15,602 34 payments
  5. INTELLIS Spinal Cord Neurostimulation $14,678 23 payments
  6. RESTORE Spinal Cord Neurostimulation $13,948 23 payments
  7. SYNCHROMED $7,238 7 payments
  8. RESTORE Spinal Cord Neurostimulation $6,708 12 payments
  9. SYNCHROMEDII $4,002 11 payments
  10. ADAPTIVESTIM $3,811 24 payments
  11. Other $9,442 228 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

4,060

Median for Pain Management: 951

Drug cost

$98,703

Median for Pain Management: $26,034

Branded share of claims

52.3%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,034 $32,771
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 998 $24,730
Pregabalin Generic 731 $15,698
Lyrica Pregabalin Brand 18 $11,172
Oxycodone Hcl Generic 252 $3,389
Fentanyl Generic 25 $2,348
Tramadol Hcl Generic 312 $2,212
Gabapentin Generic 99 $1,125
Diclofenac Sodium Generic 20 $826
Acetaminophen-Codeine Acetaminophen With Codeine Brand 39 $772

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$170,593

Of which drugs: $365

Medicare patients

266

Average age 72

Services billed

2,628

158 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 41%
Diabetes 39%
Depression 38%
Chronic kidney disease 28%
Heart failure 23%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 51 306 $238
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 89 1,290 $115

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $190
$190 — —
VYEPTI
  • Lundbeck LLC $74
$74 — —
UBRELVY
  • AbbVie, Inc. $21
$21 — —
Tirosint
  • IBSA Pharma Inc. $7
$7 — —
Licart
  • IBSA Pharma Inc. $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

619 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record